CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Xenetic Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Xenetic Biosciences Inc
945 Concord St.
Phone: (781) 778-7720p:781 778-7720 FRAMINGHAM, MA  01701  United States Ticker: XBIOXBIO
Business Summary
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
4522 Air transportation, nonscheduled
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Adam E.Logal 45 1/1/2021 8/14/2017
Chief Executive Officer, Director Jeffrey F.Eisenberg 56 10/26/2017 7/8/2016
Chief Financial Officer, Corporate Secretary James F.Parslow 58 4/24/2017 4/3/2017
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Xenetic Biosciences PLC Greener House, 66-68 Haymarket LONDON ENG United Kingdom

Business Names
Business Name
General Aircraft, Inc.
General Sales & Leasing Inc
Hesperix S.A.
8 additional Business Names available in full report.

General Information
Number of Employees: 4 (As of 12/31/2023)
Outstanding Shares: 1,540,684 (As of 3/15/2024)
Shareholders: 425
Stock Exchange: NASD
Federal Tax Id: 452952962


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024